GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
39.36
+0.00 (0.00%)
NYSE · Last Trade: Sep 4th, 5:25 AM EDT
Detailed Quote
Previous Close
39.36
Open
-
Bid
39.56
Ask
39.58
Day's Range
N/A - N/A
52 Week Range
31.72 - 44.26
Volume
1,641
Market Cap
211.96B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
1.712 (4.35%)
1 Month Average Volume
3,276,231
Chart
About GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
GSK Plc is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. The company specializes in the research, development, and manufacturing of a wide range of pharmaceuticals, vaccines, and consumer health products. GSK's portfolio covers various therapeutic areas, including respiratory diseases, HIV, oncology, immunology, and infectious diseases, with a strong emphasis on innovation and scientific advancement. Committed to addressing health challenges, GSK collaborates with various partners and stakeholders to deliver accessible healthcare solutions that meet the needs of patients and communities around the world. Read More
California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.
Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public health experts.
NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public health.
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
